SARS-CoV-2 caused the ongoing COVID-19 pandemic, and only a few treatment options are available to mitigate its impact on human health. Hence, there is a need to discover drugs that could be used to treat COVID-19. Several studies have already reported the repurposing of existing drugs to inhibit the receptor-binding domain of SARS-CoV-2. However, the emergence of COVID-19 variants may render current drug candidates ineffective. Here, we report the structure-based drug screening of the DrugBank database against the wild-type, B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2. Our study revealed that Salmeterol, Abediterol, and Lysophosphatidylglycerol are among the top candidates against all four variants. Furthermore, we showed that Salmeterol forms a stable complex with the receptor binding domain of SARS-CoV-2 variants. Further studies are needed to evaluate the clinical relevance of the drug candidates discovered. Nevertheless, this study provides insight into computational drug design that works against multiple variants of SARS-CoV-2.